Increased expression of cytochrome p450 1A1 and 1B1 genes in anti-estrogen-resistant human breast cancer cell lines

Brockdorff, B L; Skouv, Jan; Reiter, Birgit E.; Lykkesfeldt, Annè E.

doi:10.1002/1097-0215(20001215)88:6<902::aid-ijc10>3.0.co;2-c

Cited by 33 publications

(16 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CYP1B1 mRNA expression was very low (CT ~ 39) in LY2 cells and 4-OHT did not affect CYP1B1 expression (Figure 10A). These results are in contrast to a previous report showing 2–6-fold higher CYP1B1 in TAM- and fulvestrant- resistant cell lines derived from of MCF-7 cells [69]. The reason for this difference in CYP1B1 expression may be cell line- or cell culture- condition mediated.…”

Section: Resultscontrasting

confidence: 99%

Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells

et al. 2011

View full text Add to dashboard Cite

Microarrays identified miRNAs differentially expressed and 4-hydroxytamoxifen (4-OHT) regulated in MCF-7 endocrine- sensitive versus resistant LY2 human breast cancer cells. 97 miRNAs were differentially expressed in MCF-7 versus LY2 cells. Opposite expression of miRs- 10a, 21, 22, 29a, 93, 125b, 181, 200a, 200b, 200c, 205, and 222 was confirmed. Bioinformatic analyses to impute the biological significance of these miRNAs identified 36 predicted gene targets from those regulated by 4-OHT in MCF-7 cells. Agreement in the direction of anticipated regulation was detected for 12 putative targets. These miRNAs with opposite expression between the two cell lines may be involved in endocrine resistance.

show abstract

Section: Resultscontrasting

confidence: 99%

Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Theoretically, MDR1 may be involved in development of antiestrogen resistance in the DCS cell lines, as the expression level was found to be increased in some of them. Regarding the MCF-7/182 R -6 cells, which display no increase in MDR expression, we have previously demonstrated that resistance to ICI is not due to reduced intracellular antiestrogen concentration, thus excluding an MDR-mediated increased efflux of the drug (Brockdorff et al 2000). In summary, these data do not indicate a general involvement of the MDR gene in antiestrogen resistance.…”

Section: Discussionmentioning

confidence: 57%

Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens.

Crémoux

Tran-Perennou²,

Brockdorff³

et al. 2003

Endocrine-Related Cancer

View full text Add to dashboard Cite

Using a quantitative real-time RT-PCR technique we have compared the expression of a number of genes in two different human breast cancer model systems for development of acquired resistance to antiestrogens. The model system developed at the Danish Cancer Society comprises the cell lines MCF-7, MCF-7/TAM R -1, MCF-7/182 R -6 and MCF-7/182 R -7, and the model system developed at the Lombardi Cancer Research Center consists of the cell lines MCF-7/LCC1, MCF-7/LCC2 and MCF-7/ LCC9. The findings on the well-known parameters estrogen receptor (ER)α, progesterone receptor (PR) and epidermal growth factor receptor (EGFR) are in good agreement with previous reports, thus documenting the usefulness of the real-time RT-PCR technique for multiparametric RNA analysis. The gene expression levels in the two model systems were found to be quite similar in relation to ERα, AIB1 (amplified in breast cancer-1), breast cancer antiestrogen resistance gene 1 (BCAR1) and ErbB-2 mRNA expression, whereas significant differences were observed on the expression of ERβ, multidrug resistance gene 1 (MDR1), PR and EGFR. Furthermore, the presented data suggest that ERβ, AIB1, BCAR1, CYP19 and MDR1 are unlikely to be causally involved in development of antiestrogen resistance in these breast cancer cell lines.

show abstract

“…Furthermore, CYP1B1 has also been shown to be up-regulated in a breast cancer cell line treated with tamoxifen, suggesting that toxic CYP1B1 estrogen metabolites may contribute to carcinogenesis and progression in patients treated with antiestrogens (128). However, others have found that exogenous carcinogen metabolism by CYP1B1 in breast tissue may be a more important determinant in the assessment of breast cancer susceptibility than 4-OHE 2 formation (129).…”

Section: Mol Cancer Res 2006;4(3) March 2006mentioning

confidence: 99%

Pharmacogenetics and Regulation of Human CytochromeP450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention

Sissung

Price

Sparreboom

et al. 2006

Molecular Cancer Research

135

128

View full text Add to dashboard Cite

Several of the hormone-mediated cancers (breast, endometrial, ovarian, and prostate) represent major cancers in both incidence and mortality rates. The etiology of these cancers is in large part modulated by the hormones estrogen and testosterone. As advanced disease develops, the common treatment for these cancers is chemotherapy. Thus, genes that can alter tissue response to hormones and alter clinical response to chemotherapy are of major interest. The cytochrome P450 1B1 (CYP1B1) may be involved in disease progression and modulate the treatment in the above hormone-mediated cancers. This review will focus on the pharmacogenetics of CYP1B1 in relation to hormone-mediated cancers and provide an assessment of cancer risk based on CYP1B1 polymorphisms and expression. In addition, it will provide a summary of CYP1B1 gene regulation and expression in normal and neoplastic tissue. (Mol Cancer Res 2006;4(3):135 -50)

show abstract

Increased expression of cytochrome p450 1A1 and 1B1 genes in anti-estrogen-resistant human breast cancer cell lines

Cited by 33 publications

References 21 publications

Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells

Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells

Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens.

Pharmacogenetics and Regulation of Human CytochromeP450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention

Contact Info

Product

Resources

About